It’s easy to understand why most discussions about the state of venture capital investing paint a pessimistic view. Access to institutional equity dollars is increasingly limited for new entrepreneurs and early... Read more »
Acknowledging various stakeholder networks and regulatory environment variances is essential to uncover the right decision-makers in support of biologics or biosimilars